Advertise with us

World Pharma News is the leader in coverage of the most prominent pharmaceutical news.

Be featured on World Pharma News!

Want to place your Ads or News on World Pharma News?

World Pharma News is the leader in coverage of the most prominent pharmaceutical news. Advertising on World Pharma News is a smart choice for your business.

World Pharma News is one of the most visited sites on the Internet for pharmaceutical business decision-makers, professionals and stakeholders looking for the latest breaking news on the global market and in-depth research news articles. Why not put this traffic to work for you? It costs only a fraction of other on-line publications, which have far fewer readers.

We have the solutions that meet your ambitious marketing objectives. We offer flexible and price-worthy advertising opportunities for you to take advantage of. These include:

  • Skyscraper Banner, 120px / 600px (left-top, left-bottom)
  • Medium Rectangle Banner, 300px / 250px (right-top, medium and right-bottom)
  • Standard Banner, 468px / 60px (middle-top and middle-bottom)
  • Leaderboard Banner, 728px / 90px (top and bottom)
  • Newsletter Ads

The strong, innovative capabilities of World Pharma News can support your advertising, news promotion and news distribution campaigns. You will reach your objectives and an unique audience of top pharma professionals, key players and decision makers.

Don't Be Shy. If we didn’t answer all of your questions, feel free to drop us a line anytime.

Get In Touch

Facebook +19K

Twitter +60K

LinkedIn +6K

XING +7K

RSS +4K

Newsletter Subscribers +7K

Page Views +20K

FREE

Limited availability!

  • One News / Press Release publication
  • One News / Press Release publication in weekly Newsletter
  • News / Press Release featured on the first page
  • Posted to all social networks
  • Multimedia content
  • Web links
  • $0

PREMIUM

Everything you need!

  • One News / Press Release publication
  • One News / Press Release publication in weekly Newsletter
  • News / Press Release featured on the first page
  • Posted to all social networks
  • Multimedia content
  • Web links
  • Company Profile
  • $19.99

STANDARD

Great for your news!

  • One News / Press Release publication
  • One News / Press Release publication in weekly Newsletter
  • News / Press Release featured on the first page
  • Posted to all social networks
  • Multimedia content
  • Web links
  • $9.99

World Pharma News reserves the right to refuse to publish any news, press release for any reason.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Syntropy to unlock the value of scientific data in…

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syn...